Preclinical multi-target strategies for myocardial ischemia-reperfusion injury
Authors:
Open Access
- 22 August 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 967115
Abstract
Despite promising breakthroughs in diagnosing and treating acute coronary syndromes, cardiovascular disease’s high global mortality rate remains indisputable. Nearly half of these patients died of ischemic heart disease. Primary percutaneous coronary intervention (PCI) and coronary artery bypass grafting can rapidly restore interrupted blood flow and become the most effective method for salvaging viable myocardium. However, restoring blood flow could increase the risk of other complications and myocardial cell death attributed to myocardial ischemia-reperfusion injury (IRI). How to reduce the damage of blood reperfusion to ischemic myocardium has become an urgent problem to be solved. In preclinical experiments, many treatments have substantial cardioprotective effects against myocardial IRI. However, the transition from these cardioprotective therapies to clinically beneficial therapies for patients with acute myocardial infarction remains elusive. The reasons for the failure of the clinical translation may be multi-faceted, and three points are summarized here: (1) Our understanding of the complex pathophysiological mechanisms of myocardial IRI is far from enough, and the classification of specific therapeutic targets is not rigorous, and not clear enough; (2) Most of the clinical patients have comorbidities, and single cardioprotective strategies including ischemia regulation strategies cannot exert their due cardioprotective effects under conditions of hyperglycemia, hypertension, hyperlipidemia, and aging; (3) Most preclinical experimental results are based on adult, healthy animal models. However, most clinical patients had comorbidities and received multiple drug treatments before reperfusion therapy. In 2019, COST Action proposed a multi-target drug combination initiative for prospective myocardial IRI; the optimal cardioprotective strategy may be a combination of additive or synergistic multi-target therapy, which we support. By establishing more reasonable preclinical models, screening multi-target drug combinations more in line with clinical practice will benefit the translation of clinical treatment strategies.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 168 references indexed in Scilit:
- A systematic review and meta-analysis of the cardioprotective effects of remote ischaemic preconditioning in open cardiac surgeryJournal of the Royal Society of Medicine, 2012
- Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioningExperimental Physiology, 2012
- Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neuronesCardiovascular Research, 2012
- Endogenous cardioprotection by ischaemic postconditioning and remote conditioningCardiovascular Research, 2012
- Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioningCardiovascular Diabetology, 2012
- Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat heartsCardiovascular Diabetology, 2012
- Cell Death Pathways in Acute Ischemia/Reperfusion InjuryJournal of Cardiovascular Pharmacology and Therapeutics, 2011
- Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or bothThe Journal of Heart and Lung Transplantation, 2010
- Effect of Hypercholesterolemia on Myocardial Necrosis and Apoptosis in the Setting of Ischemia-ReperfusionCirculation, 2009
- Loss of cardioprotection with ageingCardiovascular Research, 2009